[Ip-health] Natco Pharma: Hyderabad-based Natco Pharma wants to make Eli Lilly’s Covid drug - The Economic Times

James Love james.love at keionline.org
Fri Dec 11 08:56:16 PST 2020


Vikas Dandekar
Natco makes an audacious move for a compulsory license on Eli Lilly's
baricitinib, a repurposed med cleared in US for use w/ remdesivir. It costs
roughly INR2500/tablet against Natco's bid to sell it at less than
INR50/tablet. Will it succeed?

More information about the Ip-health mailing list